It served, first, as a tool for exclusionary diagnosis, by ruling out molecular hallmarks of other histologically similar malignancies—such as IDH1/2 mutations in high-grade gliomas and H3F3A mutations in certain embryonal tumors—thereby consolidating the diagnosis of AT/RT. This evidence concerns the gene IDH1 and central nervous system cancer.